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Coronary artery disease (CAD) is a leading cause of death world-wide, and most cases have a complex, multifactorial
aetiology that includes a substantial heritable component. Identification of new genes involved in CAD may inform
pathogenesis and provide new therapeutic targets. The PROCARDIS study recruited 2,658 affected sibling pairs (ASPs)
with onset of CAD before age 66 y from four European countries to map susceptibility loci for CAD. ASPs were defined
as having CAD phenotype if both had CAD, or myocardial infarction (MI) phenotype if both had a MI. In a first study,
involving a genome-wide linkage screen, tentative loci were mapped to Chromosomes 3 and 11 with the CAD
phenotype (1,464 ASPs), and to Chromosome 17 with the MI phenotype (739 ASPs). In a second study, these loci were
examined with a dense panel of grid-tightening markers in an independent set of families (1,194 CAD and 344 MI
ASPs). This replication study showed a significant result on Chromosome 17 (MI phenotype; p¼0.009 after adjustment
for three independent replication tests). An exclusion analysis suggests that further genes of effect size ksib . 1.24 are
unlikely to exist in these populations of European ancestry. To our knowledge, this is the first genome-wide linkage
analysis to map, and replicate, a CAD locus. The region on Chromosome 17 provides a compelling target within which
to identify novel genes underlying CAD. Understanding the genetic aetiology of CAD may lead to novel preventative
and/or therapeutic strategies.
Citation: Farrall M, Green FR, Peden JF, Olsson PG, Clarke R, et al. (2006) Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus
on Chromosome 17. PLoS Genet 2(5): e72. DOI: 10.1371/journal.pgen.0020072
Introduction
Coronary artery disease (CAD) is the most common cause
of death in industrialised countries, and the prevalence is
increasing dramatically in developing countries. The various
clinical diagnoses that comprise CAD (e.g. angina, myocardial
infarction [MI]) are caused by atherosclerosis, a pervasive
degenerative condition in which lipid and ﬁbrous matrix is
deposited in arterial vessel walls to form atheromatous
plaques. The ﬁbrous caps of some of these plaques sited in
coronary arteries may be unstable and rupture. This will
release thrombogenic material into the lumen of the vessel
leading to coronary thrombosis, vessel occlusion, and
subsequent infarction of the myocardium, a critical condition
with high mortality. While much is known about CAD, and
about some aspects of the underlying pathology of athero-
sclerosis, new strategies for risk predication and intervention
are still needed. There thus remains considerable importance
in increasing our understanding of CAD pathophysiology.
Familial clustering of CAD has long been recognised [1],
suggesting a genetic contribution to susceptibility for this
condition. Studies of rare Mendelian forms of CAD have
shown how mutations in genes involved in low-density
lipoprotein and high-density lipoprotein metabolism/homeo-
stasis can cause premature CAD, but these mutations are
thought to explain a relatively minor fraction of familial
CAD. The majority of CAD is believed to be multifactorial
with a substantial genetic component. For instance, long-
term follow-up of monozygotic and dizygotic twin cohorts
have estimated the heritability of fatal coronary events as
57% and 38%, respectively, for men and women [2]. More-
over, there is accumulating evidence from epidemiological
studies that the genetic component of CAD risk is only
partially explained by classic risk factors that are themselves
known to be heritable [3–5]. Even though correction for
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regression dilution bias could reduce the impact of family
history of CAD as an independent risk factor, the implication
of these epidemiological studies is that susceptibility genes
for CAD might exist that are independent of hypercholester-
olemia or arterial hypertension or diabetes. These ﬁndings
are unsurprising, as studies of the pathophysiology of
atherosclerosis have shown the importance of pathways
involved in inﬂammation and innate immunity [6,7]. Con-
sequently, the intriguing possibility exists that identiﬁcation
of susceptibility genes might highlight novel biological
pathways involved in atherosclerotic plaque formation and/
or rupture, providing opportunities for prevention and
therapeutic intervention. On the other hand, susceptibility
might be determined principally by novel genes involved in
well-known pathways (e.g. cholesterol metabolism). These
possibilities have motivated large-scale genetic projects to
map and identify susceptibility genes for CAD in an unbiased
manner with respect to gene function.
Published genetic linkage studies have implicated several
loci for CAD. The ﬁrst such linkage study was from Finland
and showed linkage of premature CAD to loci on Chromo-
somes 2q21.2–22 and Xq23–26 [8]. Subsequent studies from
Germany reported linkage to Chromosome 14q32.2 [9], from
Iceland to Chromosome 13q12–13 [10], from the United
States in the GENECARD study to Chromosomes 3q13 and
5q31 (with linkage in subgroups to Chromosomes 1q25, 7p14,
19p13) [11] and another U.S. study to Chromosome 1p34–36
[12]. The Icelandic locus was replicated in population-based
studies from Iceland and England, with different haplotypes
of the ALOX5AP gene (encoding 5-lipoxygenase activating
protein) associated with CAD in the two countries, and the
Icelandic haplotype was also associated with stroke in Iceland
and in Scotland [10,13]. The Chromosome 2 linkage identiﬁed
by the BHF Family Heart Study [14] was also detected in two
previous studies [8,12], and provides a promising region for
further investigation.
The status of CAD loci which have not been replicated is
less clear. Differences in the population studied and/or in the
selection criteria used might result in selection for different
genetic effects in this heterogeneous disorder. However, the
lack of replication might also be expected given that most of
these linkage studies had rather low power relative to the
anticipated effect size of CAD susceptibility genes. The
published linkage screens have ranged in size from 156–
1,933 families (;200–2,400 ASPs) and the linkage statistics
reported have sometimes been suggestive rather than of ﬁrm
genome-wide signiﬁcance, suggesting that some postulated
loci may be false positives. None of the published studies have
had the statistical power to replicate a speciﬁc locus. Rather,
the signal-to-noise ratio is such that these studies have had
borderline power to detect individual susceptibility genes, and
so each will tend by chance to identify a different selection.
The PROCARDIS study was founded as a European
collaborative project to assemble a sufﬁciently large number
of families to map the modestly sized susceptibility genes that
might plausibly be hypothesised to contribute to CAD risk.
We present here the results of the ﬁrst phase of the study, a
linkage study of 2,658 ASPs from 2,036 families with multiple
CAD siblings.
Results
Affected sibling pairs (ASPs) were identiﬁed in the families
by applying two phenotypic criteria: 1) a broad CAD
deﬁnition of disease status in the affected sibling(s), (i.e. MI,
symptomatic acute coronary syndrome [SACS], chronic stable
Table 1. Country of Residence and Degree of Relatedness for Affected Sib-Pairs in the Genome-Screen and Replication Cohorts
Country Relationship Genome-Screen Replication
CAD MI CAD MI
Germany Full-sib 234 124 3 2
Half-sib 11 7 0 0
Italy Full-sib 219 133 86 51
Half-sib 11 4 0 0
Sweden Full-sib 292 192 7 2
Half-sib 31 27 0 0
United Kingdom Full-sib 630 234 1,054 281
Half-sib 36 18 44 8
All 1,464 739 1,194 344
DOI: 10.1371/journal.pgen.0020072.t001
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Synopsis
Coronary artery disease (CAD), which presents clinically as a heart
attack (myocardial infarction) or angina, is a leading cause of death
world-wide. The aetiology of CAD is complex with a substantial
heritable component. Although there is a huge knowledge-base
detailing many aspects of the underlying pathophysiology of CAD, it
is likely that undiscovered pathways exist. Positional cloning
projects can identify novel susceptibility genes; in the first step
genome-wide linkage screens are used to assign loci to specific
chromosomes.
The authors have collected 2,036 CAD families from four European
countries, in order to maximise the power of detecting genes that
confer modest risks. A genome-wide linkage scan identified three
promising regions for intensive study; one of the linked regions
(Chromosome 17) was confined to families with multiple cases of
myocardial infarction and was replicated in a second independent
series of families. In addition the linkage scan confirmed a previously
identified locus on Chromosome 2. These results demonstrate that
novel CAD susceptibility genes are tractable to positional cloning
which promises to lead to the identification of new molecular
insights into this condition, and hopefully, new treatments.
angina or coronary revascularisation at age , 66 y), with each
ASP containing at least one proband with MI or SACS, or 2) a
narrow deﬁnition of disease based on a clinical history of MI
at age , 66 y. Table 1 shows the country of residence of the
ASPs in addition to the number of full- and half-siblings
conﬁrmed or identiﬁed in a RELPAIR [15] relationship
analysis. Overall 5% (133/2,658) of the ASPs were reclassiﬁed
as half-sibling pairs. A further 70 individuals were excluded
from analysis as they were apparently unrelated (55 individ-
uals) or possibly distantly related (15 individuals) to the
recorded family structure.
We ﬁrst undertook an initial genome-screen (Figure 1) for
1,464 CAD ASPs (Figure 1A) and 739 MI ASPs (Figure 1B)
genotyped with 446 microsatellite markers. Three regions of
tentative linkage were identiﬁed by multipoint linkage
analysis using the MLSix programme on Chromosomes 3
(CAD phenotype, log of the odds [LOD]¼ 1.52), Chromosome
11 (CAD phenotype, LOD ¼ 1.66), and Chromosome 17 (MI
phenotype, LOD ¼ 2.85). The genome-wide signiﬁcance of
these statistics (i.e. allowing for the multiple signiﬁcance
testing inherent in a genome-screen) was estimated by
computer simulation as p ¼ 0.81 (CAD, Chromosome 3), p ¼
0.71 (CAD, Chromosome 11) and p ¼ 0.08 (MI, Chromosome
17). These results were supported by an alternative multi-
point linkage analysis method using the Merlin programme
(see Figure S1 for detailed results). For instance, the Merlin
analysis showed linkage to the MI phenotype on Chromosome
17 (LOD¼ 3.19; location¼ 61 cM;1 LOD support interval¼
41–77 cM).
In order to further test the potential importance of the loci
identiﬁed in the linkage analysis, these regions were tested in
an additional sample of 1,194 CAD ASPs and 344 MI ASPs
(details shown in Table 1). Table 1 shows that families
recruited in the United Kingdom were over-sampled in the
Figure 1. A Genome-Wide Scan of CAD and MI
A genome-wide scan of CAD—broad CAD phenotype, 1,464 ASPs (A), and MI—narrow phenotype, 739 ASPs (B). Genetic location (abscissa) is scaled in
Kosambi cM. LOD (ordinate) denotes themaximumLOD score statistic. The solid line showsmultipoint LODs calculated at regular intervals; the vertical bars
showsingle-point LODs (i.e. calculatedat eachmicrosatellitemarker). The locationof eachmicrosatellitemarker is shownby an external tick on the abscissa.
DOI: 10.1371/journal.pgen.0020072.g001
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replication phase of the project (and German and Swedish
families were under-sampled), which simply reﬂects differ-
ences in the timing of ASP recruitment across the four
countries. Additional grid-tightening markers (eight markers
on Chromosome 3, seven markers on Chromosome 11, and 25
markers on Chromosome 17) were included to maximise the
recovery of identity-by-descent information for these regions.
Figure 2 summarises the results of these replication experi-
ments. There was insigniﬁcant evidence of linkage on
Chromosome 3 to the broad CAD phenotype (p¼ 0.056), with
a peak LOD ¼ 0.7 mapping 11.9 cM outside the 1 LOD
support interval identiﬁed in the genome-wide screen (Table
2). There was no evidence for linkage to Chromosome 11 in the
broad CAD replication cohort. In contrast, the MI suscepti-
bility locus on Chromosome 17 showed signiﬁcant evidence
for linkage (p ¼ 0.003) at location 67 cM (Table 2). After
allowance for multiple testing of three independent hypoth-
eses generated in the initial genome-wide screening phase of
the experiment, the linkage to Chromosome 17 was signiﬁcant
(p ¼ 1 – (1 – 0.003)3 ¼ 0.009) [16]. Table 2 shows maximum
likelihood estimates and 95% conﬁdence intervals (CI) for the
recurrence risk ratio (ksib) associated with the linked region on
Chromosome 17 for MI phenotype. The linked region was
further investigated in the replication cohort with CAD (1,194
ASPs); there was weak support for linkage between Chromo-
some 17 and the broad CAD phenotype (p¼0.156). Finally, an
analysis of the combined data from the genome-wide screen
and replication cohorts showed linkage to the MI phenotype
on Chromosome 17 (LOD ¼ 2.68; location ¼ 69 cM; 1 LOD
support interval¼ 63–79 cM).
An exclusion analysis (Figure 3) was performed for CAD
(Figure 3A) or MI (Figure 3B) ASPs by calculating the largest
ksib at each genetic location associated with a LOD of2 [17].
Using this strict exclusion criterion, 85% of the autosomal
genome was excluded for a locus-speciﬁc effect of ksib¼ 1.24
(CAD phenotype) and ksib ¼ 1.42 (MI phenotype).
Discussion
Susceptibility genes for human complex diseases are
believed to confer modest risks and hence genetic linkage
to such loci may be difﬁcult to replicate. So our ﬁnding that a
region of tentative linkage to the MI phenotype identiﬁed on
Chromosome 17 in a genome-wide screen (p ¼ 0.08) was
replicated in an independent cohort of families (p ¼ 0.009,
corrected for multiple comparisons) is important and
provides a target for further positional cloning studies.
It is well known that estimates of genetic effect sizes from
genome-wide screens are frequently upwardly biased [18] and
that more realistic estimates can be obtained in independent
replication cohorts. Table 2 provides estimates of the genetic
effect size (and their 95% CI) associated with linkage to
Chromosome 17 that were obtained by a bootstrap re-
sampling procedure. The peak LOD obtained in the genome-
screen was at map location 50.7 cM which was associated with
an effect ksib ¼ 1.21; in the replication data, the effect size
estimated at the same location was considerably smaller (ksib
¼ 1.04). The LOD 1 support interval for localising the MI
susceptibility gene in the genome-wide screen was broad (42–
79 cM) which is typical for complex diseases [19]. The peak
LOD in the replication dataset reassuringly falls within this
interval at location 67.0 cM (ksib at this position was 1.29 in
the replication cohort).
As the linked region on Chromosome 17 appears to be
speciﬁc for the MI phenotype, with no evidence for linkage to
the broad CAD phenotype in the replication set of ASPs (p .
0.156), it is important to consider the possible reasons for this
Figure 2. Replication Analysis of Chromosomes 3, 11, and 17 Linkage
Peaks
Replication analysis, in independent ASPs, of the three Chromosomes (3,
11, and 17) most strongly implicated by the initial genome-wide screen.
(A and B) show the results for the broad CAD phenotype and
Chromosomes 3 and 11 (1,194 ASPs). (C) shows the results for the
narrow MI phenotype and Chromosome 17 (344 ASPs). Genetic location
(abscissa) is scaled in Kosambi cM. LOD (ordinate) denotes the MLS
statistic. The solid line shows multipoint LODs calculated at regular
intervals; the vertical bars show single-point LODs (i.e. calculated at each
microsatellite marker). The location of each microsatellite marker is
shown by an external tick on the abscissa.
DOI: 10.1371/journal.pgen.0020072.g002
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phenomenon. Current knowledge of the pathophysiological
processes that lead to CAD indicate that they are highly
diverse, and to a large extent not understood in full detail. In
addition the CAD disease entity is heterogeneous, consisting
of four major diagnostic outcomes: MI, angina, unstable
angina, and coronary revascularisation events [20]. There is
considerable overlap between these outcomes, yet they differ
signiﬁcantly in their underlying pathophysiology. Coronary
artery atherosclerosis forms the basis for all four disease
events, yet MI and unstable angina require a further step of
rapid deterioration in coronary artery blood-ﬂow. This last
step is, in addition to atherosclerotic build-up, determined by
a complex interplay between factors such as plaque stability,
inﬂammatory response, platelet function and the coagulation
cascade [21]. A modest level of atherosclerosis can be
sufﬁcient for some individuals to suffer an acute coronary
event, but others with severe coronary artery stenosis never,
or only late in life, suffer a clinically detectable MI. An
understanding of how this kind of phenotypic, and poten-
tially genotypic, heterogeneity affects our linkage results is
important when analyzing large sets of data [22]. Further
statistical evaluation, including ordered subset analysis and
quantitative-trait linkage analysis, could be usefully applied
to promising linked regions in this and other genome screens.
Thus, different sets of CAD patients will plausibly differ
signiﬁcantly in their linkage results, a conclusion supported
by the fact that few of the loci in the CAD linkage studies
published hitherto overlap with each other [8–12,14].
The region of linkage to MI in the present study, ﬂanked by
markers D17S921 at 17p11.2 (40 cM; genomic position
14,170,191 in the National Centre for Biotechnology Infor-
mation 35.1 assembly) and D17S787 at 17q21 (79 cM; position
50,637,083), spans the centromere and includes over 36
megabases of DNA containing over 300 genes of known
function and about as many again predicted genes. This
interval contains numerous genes that are plausible candi-
dates for involvement in CAD, therefore our future research
is focused on reﬁning the region genetically by means of high
density SNP coverage, using the PROCARDIS case-control
collection and our trio families, and by an analysis of
quantitative trait loci (QTL) for CAD intermediate pheno-
types measured in the affected sib-pair families. There are
published QTLs close to this region that may provide clues.
For example, two QTLs for low-density lipoprotein choles-
terol map just outside the PROCARDIS region to 17q23.2–
25.3 [9] and 17q24.2–25.3 [23]. In familial combined hyper-
lipidemia pedigrees, a QTL for apoB at 17p11–q21 [24] is
within our mapped region, as is a QTL affecting low-density
lipoprotein peak particle diameter at 17q21.33 [25]. QTLs for
Table 2. Peak LODs on Chromosomes 3 and 11 (CAD Phenotype) and 17 (MI Phenotype)
Chromosome Phenotype Family Set LOD p-Value Location (cM) 1 LOD Support Interval (cM) ksiba 95% CI (ksiba) ASPs (n)
3 CAD Genome-wide screen 1.52 0.81b 19.4 0–27 1.13 1.02–1.24 1,464
3 CAD Replication 0.70 0.056c 38.9 N/A ND ND 1,194
11 CAD Genome-wide screen 1.66 0.71b 66.2 57–76 1.11 1.02–1.22 1,464
11 CAD Replication 0.00 1.00c 60–80 N/A ND ND 1,194
17 MI Genome-wide screen 2.854 0.08b 50.7 42–79 1.21 1.07–1.45 739
17 MI Replication 1.607 0.003c 67.0 62–79 1.29 1.05–1.61 344
aFull-sibling recurrence risk ratio estimate.
bp-Value corrected for genome-wide multiple testing.
cLocation-specific p-value.
N/A, not applicable; ND, not done.
DOI: 10.1371/journal.pgen.0020072.t002
Figure 3. Exclusion Linkage Analysis
Exclusion linkage analysis in the initial genome-wide screen set of
families. (A) shows the results for the CAD—broad phenotype, and (B)
shows the results for the MI—narrow phenotype. Genetic location
(abscissa) is scaled in Kosambi cM. The exclusion limit (ksib associated with
a LOD¼2) at each location is plotted. The location of each microsatellite
marker is shown by an external tick on the abscissa.
DOI: 10.1371/journal.pgen.0020072.g003
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body mass index in two National Heart, Lung & Blood
Institute study subsets map to markers D17S947 at 17p12,
coincident with a QTL for leptin [26], and D17S2196 at
17p11.2 lie close to the PROCARDIS MI linkage region.
Tentative QTLs for smoking behaviour from the Framingham
Heart Study map to 17q21.2 and 17q25.3, which is intriguing
given the strong links between smoking and CAD risk [27].
A region of linkage using ordered subset analysis in 26
young-onset CAD families has been identiﬁed between
markers D17S787 and D17S944 (50,637,083–58,790,038 Na-
tional Centre for Biotechnology Information 35.1 assembly)
[14] which adjoins our Chromosome 17 linkage; given the
limited resolution of linkage mapping of complex traits [19],
these two loci plausibly overlap. A similar deduction may be
made for Chromosome 2 (Figure 1A) in which a broad region
of linkage (maximum LOD 1.42, CAD phenotype) overlaps
distally with earlier ﬁndings [8,12,14]. These results encourage
detailed examination of these loci in positional cloning and
large-scale, gene-association studies.
In conclusion, the results from the PROCARDIS genome-
wide linkage analysis are important because they identify a
novel replicated locus for MI on Chromosome 17. In addition,
our CAD linkage results are consistent with a CAD
susceptibility locus mapping to Chromosome 2. The lack of
evidence for other linked loci suggests that the heritable
component of coronary artery disease and MI may be
composed of many genes, with few of them having sufﬁcient
effect to permit mapping by genetic linkage even in studies of
this size involving thousands of affected sibling pairs.
Materials and Methods
Family collections. Ascertainment criteria for PROCARDIS pro-
bands were MI or SACS, on the assumption that the latter represents
a similar pathological process according to modiﬁed World Health
Organisation diagnostic criteria [28,29] before the age of 66 y [30].
Diagnosis of MI required documentation of two or more of: (a) typical
ischemic chest pain, pulmonary oedema, syncope or shock; (b)
development of pathological Q-waves and/or appearance or disap-
pearance of localized ST-elevation followed by T-wave inversion in
two or more standard electrocardiograph leads; (c) increase in
concentration of serum enzymes consistent with MI (e.g. creatine
kinase more than twice the upper limit of normal). Diagnosis of SACS
required documentation of hospitalization for one of the following
indications: (a) unstable angina diagnosed by typical ischemic chest
pain at rest associated with reversible ST-depression in two or more
standard electrocardiograph leads; (b) thrombolysis for suspected MI
(as indicated by localized ST-elevation in two or more standard
electrocardiograph leads) even without later development of T-wave
inversion, Q-waves, or a signiﬁcant enzyme rise; or (c) emergency
revascularization (i.e. during same admission) following presentation
with typical ischemic chest pain at rest. Probands completed
questionnaires in order to recruit affected siblings with a range of
CAD diagnoses at age , 66 y (MI, SACS, chronic stable angina, or
intervention for coronary revascularization), who were then invited
to participate in the study if their diagnoses were conﬁrmed. Parents
and up to four unaffected siblings per family were recruited wherever
possible to augment the recovery of linkage phase information.
Informative families were recruited in Germany, Italy, Sweden, and
the United Kingdom; 99.5% of the study participants reported having
a white European ancestry. The protocol was approved by the Ethics
Committees of the participating institutions and all participants gave
written, informed consent.
DNA extraction and microsatellite genotyping. DNA was extracted
from 9 ml EDTA-anticoagulated samples of frozen whole blood using
Gentra Systems PUREGENE kits (Flowgen, Lichﬁeld, United King-
dom) according to the manufacturer’s instructions, and its concen-
tration determined ﬂuorimetrically using SYBRt Green. DNA was
plated and genotyped for the ABI MD10 (Applied Biosystems,
Warrington, United Kingdom) set of microsatellite markers using
ABI 3700 capillary sequencing equipment [31]. All microsatellite
genotyping was carried out at Oxagen Limited (Abingdon, Oxford-
shire, United Kingdom). Genotyping was carried out blind of pedigree
structure and disease status. Genotypes were called using the
automated functions within the ABI Genotyper software andmanually
checked independently by two operators. All discrepancies were
reviewed and re-genotyped if no consensus call was made. Following a
relationship analysis (see below), genotypes were checked for
Mendelian inconsistencies [32]. After a further round of re-genotyp-
ing, any remaining inconsistent genotypes were ﬂagged as ‘‘missing’’
and removed from any subsequent analysis. The accuracy of genotyp-
ing can be estimated in 19 pairs of siblings that, after relationship
analysis, were proven to be monozygotic twin-pairs. 5,741/5,759
(99.7%) of their genotypes were concordant. For these 19monozygotic
twins, no genotypes were ﬂagged as ‘‘missing’’ during QC.
Additional grid-tightening markers were genotyped for the linked
regions on Chromosomes 3 (eight markers), 11 (seven markers), and
17 (25 markers); details are included in Table S1. A total of 15
markers (MD10þ grid-tightening markers) were completely excluded
from further analysis following QC analysis.
Statistical analysis. Genetic relationships between cognate relatives
were conﬁrmed in an analysis using the RELPAIR program [15] with
all genotyped microsatellite markers. If sibling pairs were found to be
consistent with being related at the half-sib level, their family
structures were revised and included in subsequent analyses.
Individuals found to be unrelated to their recorded family were
excluded from all subsequent analyses. Any remaining inconsistent
genotypes were subsequently marked as missing. Two further grid-
tightening markers were eliminated as they showed excessive non-
Mendelian inheritance and Hardy-Weinberg disequilibrium. The
genetic map for all of the genome-screen and majority of the grid-
tightening markers was extracted from the Rutgers sex-averaged map
[33]. The Rutgers map is an integrated genetic map in which physical
sequence data was used to establish marker order; genetic map
distances were estimated by maximum likelihood methods using
meiotic mapping data from Centre d’Etude Polymorphism Humaine
and DeCode genotype databases. The locations of ﬁve grid-tightening
markers absent from the Rutgers map were linearly interpolated with
respect to ﬂanking markers that were included in the Rutgers map.
Non-parametric linkage analysis was undertaken using the com-
puter program MLSix, to compute single-point and multi-point
maximum LOD score (MLS) statistics [34,35] for affected full and half
sib-pairs [17]. For autosomal loci, two parameters were included to
model additive and dominance effects on susceptibility, and LODs
were maximized under the ‘‘possible triangle’’ constraints [34]. For X-
linked loci, LODs were maximised under analogous linear constraints
[36] for same or mixed-sex full-sibs and informative half-sibs
(maternal half-brothers and half-brother-sisters and half-sisters).
ASPs drawn from affected sibships of size  2 were equally weighted
in the MLS calculations. All ASPs include at least one affected sib,
complying with the PROCARDIS proband deﬁnition (MI or SACS at
age , 66 y). Identity-by-descent vectors for the full and half-sib pairs
for each sibship were calculated by the Merlin program [37], using the
‘‘minx’’ version of the program for X-linked data. Marker allele
frequencies were estimated by gene counting pooling information
across the four countries and across genome-screen and replication
cohorts where available. In regions of linkage, the peak LOD is
associated with a measure (recurrence risk ratio in full-siblingsksib)
of the genetic effect size for this susceptibility gene; 95% CI for this
ksib estimate were calculated using a bootstrapping technique with
1,000 replicates [38]. Exclusion analysis was performed using MLSix;
the maximization function was modiﬁed to estimate the ksib
associated with a MLS ¼ 2 (a strict exclusion threshold) at each
genetic location. This analysis is able to show in regions that show
little or no evidence of linkage, that there is sufﬁcient identity-by-
descent information to conﬁdently exclude susceptibility genes of
modest effect sizes. The statistical signiﬁcance of the MLS statistics
were established by a computer simulation which modeled the family
structures (including the patterns of missing parental genotypes and
the small proportion of families with more than two affected sibs),
marker density and informativity [17]; 1,000 replicates of a complete
genome-wide screen were simulated. To interpret the signiﬁcance of
the MLS statistic in the genome-wide screen (i.e. allow for multiple
testing), the number of MLS statistics greater than desired threshold
across all chromosomes was recorded. To interpret the signiﬁcance of
the MLS statistic in the replication experiment, the number of MLS
greater than desired threshold at a one location (i.e. one test at one
speciﬁc location) was recorded.
The authors had full access to the data and take responsibility for its
integrity. All authors have read and agree to themanuscript as written.
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Supporting Information
Figure S1. A Genome-Wide Scan of CAD and MI
A genome-wide scan of CAD—broad CAD phenotype, 1,464 ASPs (A)
and MI—narrow phenotype, 739 ASPs (B). Genetic location (abscissa)
is scaled in Kosambi M. The ordinate denotes the Kong & Cox LOD
score [39] calculated using the Merlin computer programme [37]. The
solid line shows multipoint LOD scores calculated at regular
intervals. For details of the Merlin programme see http://www.sph.
umich.edu/csg/abecasis/Merlin/index.html
Found at DOI: 10.1371/journal.pgen.0020072.sg001 (586 KB TIF).
Table S1. 40 Additional Grid-Tightening Markers on Chromosomes 3,
11, and 17
Found at DOI: 10.1371/journal.pgen.0020072.st001 (62 KB DOC).
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